Newsroom | 1668 results

PORTO, Portugal--(BUSINESS WIRE)--FairJourney Bio (FJBio), a global leader in antibody discovery and development, announced today that its Chief Executive Officer, Dr. Werner Lanthaler, will present at the J.P. Morgan 2026 Healthcare Conference, taking place from January 12 – 15, 2026 in San Francisco, CA. With more than a decade of expertise, FJBio has supported over 250 clients across Pharma, Biotech and Academia and contributed to more than 19 antibodies advancing to clinical stage developme...

LOS ANGELES--(BUSINESS WIRE)--AHF Rose Parade® Float Honors ‘Food for Health’ Wildfire and Hunger Relief Efforts...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced an agreement with the U.S. government designed to reduce drug costs for Americans, reinforcing the company’s long-standing commitment to U.S.-based innovation, affordability, and global health leadership. “This agreement reflects a foundational commitment to both affordability and future innovation, a commitment that we have long seen as essential to shaping the future of healthcare,” said Daniel O’Day, C...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that Keeley Wettan will be appointed Executive Vice President, General Counsel, Legal & Compliance effective immediately. She will join the company’s senior leadership team and report to Chairman and Chief Executive Officer Daniel O’Day. Ms. Wettan has held increasingly senior legal leadership roles within Gilead during her 14-year tenure, most recently as Senior Vice President leading the Global Lega...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced positive topline results from the Phase 3 ARTISTRY-2 trial. The double-blind trial evaluated the treatment responses of adults with HIV who are virologically suppressed switching from BIKTARVY® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF) to a fixed-dose combination of bictegravir 75 mg/lenacapavir 50 mg (BIC/LEN). BIC/LEN efficacy was found to be statistically non...

LOS ANGELES--(BUSINESS WIRE)--New Billboards Mark AHF’s 50 Country Milestone, Promote Ease of Testing...

SHARON HILL, Pa.--(BUSINESS WIRE)--26Health, a Central Florida-based family health center committed to providing comprehensive care to underserved communities, today announced plans to open its first entity-owned pharmacy in Orlando. This initiative is being made possible through an expansion of the health center’s partnership with NuvemRx, a leading tech-enabled pharmacy service for community health providers. Healthcare providers often face significant challenges in standing up and optimizing...

CIUDAD DE MÉXICO--(BUSINESS WIRE)--Sin cooperación regional, Latinoamérica no podrá enfrentar adecuadamente la próxima emergencia sanitaria. Este fue el mensaje central del panel de alto nivel organizado por el Instituto AHF de Salud Pública Global y el Laboratorio de Políticas Públicas en Salud de la Universidad de Miami, en el que líderes de la región coincidieron en que es urgente construir una arquitectura latinoamericana capaz de responder como bloque ante futuras crisis sanitarias. El web...

MEXICO CITY--(BUSINESS WIRE)--Without regional cooperation, Latin America will not be able to adequately confront the next health emergency. This was the central message of the high-level panel organized by the AHF Global Public Health Institute and the University of Miami’s Public Health Policy Lab, where regional leaders agreed that it is urgent to build a Latin American architecture capable of responding as a bloc to future health crises. The webinar, moderated by Dr. Jorge Saavedra, Executi...

DUBLIN--(BUSINESS WIRE)--The "Smart Syringes Market Forecast to 2033" has been added to ResearchAndMarkets.com's offering. The global smart syringes market is set for robust growth, with an estimated size of USD 1.05 billion in 2024 and a projection to reach USD 2.22 billion by 2033. This represents a CAGR of 8.7% from 2025 to 2033, driven by a heightened focus on safety for both patients and healthcare workers. Rising cases of Needle Stick Injuries (NSIs) and transmission of blood-borne infect...